Gilead Sciences reported adjusted earnings of $2.01 per share, surpassing the consensus of $1.94, with sales hitting $7.08 billion, beating the consensus of $6.94 billion. Total second-quarter product sales increased 2%, excluding Veklury, up 4% to $6.9 billion, driven by higher HIV, Livdelzi, and Trodelvy sales.

Biktarvy sales rose by 9% to $3.5 billion, while Descovy sales increased by 35% to $653 million. Liver Disease portfolio sales decreased by 4% to $795 million, and Veklury sales dropped by 44% to $121 million. Cell Therapy product sales also decreased by 7%.

Trodelvy sales saw a 14% increase to $364 million, with a product gross margin of 78.7% in Q2 2025. Non-GAAP product gross margin was 86.9% in the same period, driven by product mix. Gilead authorized a new $6.0 billion stock repurchase program.

Gilead raised its fiscal 2025 adjusted earnings guidance to $7.95-$8.25 per share and increased sales guidance to $28.3 billion-$28.7 billion. Veklury sales are expected to reach $1 billion, down from the previous $1.4 billion forecast. Gilead also announced a strategic partnership agreement with the Global Fund to Fight AIDS.

Analysts at Truist Securities upgraded Gilead from Hold to Buy, raising the price forecast from $108 to $127. GILD stock was trading higher by 9.07% to $120.30. Goldman Sachs sees positive updates and potential policy dynamics as key drivers for stock performance.

Read more at Yahoo Finance: Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears